{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:52:12Z","timestamp":1793256732588,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Initially developed for type 2 diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now emerging as promising candidates for modifying the course of neurodegenerative diseases. This potential stems from the presence of GLP-1 and its receptors within the central nervous system (CNS), where their signaling activity influences critical processes like synaptic plasticity, neuroinflammation, insulin signaling, and cellular energy management. In fact, preclinical models of both Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD) have shown that GLP-1RAs can reduce neuroinflammation, improve mitochondrial function, and enhance the clearance of toxic proteins (proteostasis), leading to benefits in cognition and the survival of dopaminergic neurons. Yet, when tested in humans, the picture has been more nuanced and less straightforward. Early clinical trials in AD have produced mixed cognitive signals, though they have shown intriguing biological effects, such as preserved cerebral glucose metabolism with liraglutide on FDG-PET scans. In contrast, the evidence in PD has been more consistent, with agents like exenatide and lixisenatide demonstrating motor benefits, although one trial with a pegylated exendin (NLY01) did not meet its primary endpoint. The definitive test will come from large, ongoing phase 3 programs, such as the EVOKE and EVOKE+ trials for semaglutide. Should these trials are successful, GLP-1RAs could become a cornerstone of earlier, mechanism-based intervention strategies for neurodegenerative diseases.<\/jats:p>","DOI":"10.3389\/fendo.2025.1708565","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:12:50Z","timestamp":1763615570000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["GLP-1 receptor agonists in Alzheimer\u2019s and Parkinson\u2019s disease: endocrine pathways, clinical evidence, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Ayush","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Parhizgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2016.00108","article-title":"In alzheimer\u2019s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2025.1601602","article-title":"GLP-1R as a potential link between diabetes and Alzheimer\u2019s disease","volume":"17","author":"Li","year":"2025","journal-title":"Front Aging Neurosci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/WNR.0b013e32832fbf14","article-title":"Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system","volume":"20","author":"Hamilton","year":"2009","journal-title":"Neuroreport"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00250.2023","article-title":"Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss","volume":"326","author":"Buller","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/ph18050614","article-title":"Antidiabetic GLP-1 receptor agonists have neuroprotective properties in experimental animal models of alzheimer\u2019s disease","volume":"18","author":"Urkon","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.3390\/ijms23052687","article-title":"Alzheimer\u2019s disease as type 3 diabetes: common pathophysiological mechanisms between alzheimer\u2019s disease and type 2 diabetes","volume":"23","author":"Michailidis","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists-effects beyond obesity and diabetes","volume":"13","author":"Wilbon","year":"2023","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/alz.089799","article-title":"Evaluation of Novel GLP-1 analogue in the treatment of Alzheimer\u2019s disease","volume":"20","author":"Edison","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-025-01226-z","article-title":"Incretin hormones GLP-1 and GIP normalize energy utilization and reduce inflammation in the brain in alzheimer\u2019s disease and parkinson\u2019s disease: from repurposed GLP-1 receptor agonists to novel dual GLP-1\/GIP receptor agonists as potential disease-modifying therapies","volume":"39","author":"H\u00f6lscher","year":"2025","journal-title":"CNS Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"109952","DOI":"10.1016\/j.neuropharm.2024.109952","article-title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson\u2019s and Alzheimer\u2019s disease clinical trials: A revolution in the making","volume":"253","author":"H\u00f6lscher","year":"2024","journal-title":"Neuropharmacology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30231-3","article-title":"Brain insulin resistance in Alzheimer\u2019s disease and related disorders: mechanisms and therapeutic approaches","volume":"19","author":"Kellar","year":"2020","journal-title":"Lancet Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0353","article-title":"GLP-1RA and SGLT2i medications for type 2 diabetes and alzheimer disease and related dementias","volume":"82","author":"Tang","year":"2025","journal-title":"JAMA Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.21016","article-title":"Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity","volume":"8","author":"Lin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30173-3","article-title":"Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial","volume":"19","author":"Cukierman-Yaffe","year":"2020","journal-title":"Lancet Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012990.pub2","article-title":"GLP-1 receptor agonists for Parkinson\u2019s disease","volume":"7","author":"Mulvaney","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B25","doi-asserted-by":"publisher","first-page":"106159","DOI":"10.1016\/j.neubiorev.2025.106159","article-title":"Role of glucagon-like peptide-1 on amyloid, tau, and \u03b1-synuclein: target engagement and rationale for the development in neurodegenerative disorders","volume":"173","author":"Au","year":"2025","journal-title":"Neurosci Biobehav Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"107770","DOI":"10.1016\/j.phrs.2025.107770","article-title":"Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges","volume":"216","author":"Zhou","year":"2025","journal-title":"Pharmacol Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","article-title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson's disease","volume":"31","author":"Hong","year":"2024","journal-title":"J BioMed Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12883-016-0606-3","article-title":"A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"16","author":"McGhee","year":"2016","journal-title":"BMC Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/AS9.0000000000000541","article-title":"Bariatric surgery is associated with reduced incidence of mild cognitive impairment and alzheimer disease and related dementias: A retrospective cohort study","volume":"6","author":"Chen","year":"2025","journal-title":"Ann Surg Open"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00400","article-title":"The therapeutic potential of metformin in neurodegenerative diseases","volume":"9","author":"Rotermund","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159381","article-title":"Metformin prevents nigrostriatal dopamine degeneration independent of AMPK activation in dopamine neurons","volume":"11","author":"Bayliss","year":"2016","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei","year":"2024","journal-title":"Transl Neurodegener"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: A report of the american college of cardiology solution set oversight committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1708565\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:12:51Z","timestamp":1763615571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1708565\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":35,"alternative-id":["10.3389\/fendo.2025.1708565"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1708565","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1708565"}}